|
Dr
Alison Webster
Director of the Infectious Diseases Medicines Development Centre,
GlaxoSmithKline Dr Alison Webster is Director of Infectious Diseases Medicines
Development Centre at GlaxoSmithKline, where her role is to develop and implement
the strategy for the clinical development of several antibiotics and antivirals.
Her experience in the influenza area has encompassed design of clinical studies
with zanamivir, interpretation and publication of results, authoring of dossiers
for regulatory submission, and interactions with regulatory agencies in the assessment
of safety and efficacy of this product In the context of pandemic planning,
she has represented the company and given presentations at meetings with the WHO,
EFPIA and IFPMA. Within the UK, she has led the clinical component of GSK's submission
to NICE for the appraisal of zanamivir, and submitted oral evidence to the committee
preparing the Royal Society/Academy of Medical Sciences report on pandemic influenza
in 2006. Dr Webster is also Honorary Lecturer in Medical Virology at Imperial
College London. | 
You
are here: 